A Phase 3 interventional study of Active comparator: Niraparib and placebo in Ovarian Neoplasms and Platinum Sensitive Ovarian Cancer, sponsored by Tesaro, Inc.. Completed at 112 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.
Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 7 in phase 3, and was the 3rd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
University of Miami · Sites in United States, Nigeria
Ages 18+ · Women only
MedSIR · Sites in Spain
Ages 18+ · Women only
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+ · Women only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 596 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 41 across the 44 interventional studies. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
31 studies in Ovarian Neoplasms by GlaxoSmithKline: 5 open now, 7 under way, 5 of them phase 3. Of 22 finished, 16 (73%) have results posted.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 5th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2013, is one of 7 in phase 3, and was the 13th registered.
GlaxoSmithKline’s Ovarian Neoplasms studies by the year they started, since 1997.
2 of the studies testing niraparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT06594679Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing niraparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.
The primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (PFS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2:1 Ratio administered once daily continuously during a 28 day cycle.
Drug: Active comparator: Niraparib
Administered once daily continuously over a 28 day cycle.
Drug: placebo
Niraparib vs placebo 2:1 ratio
Also known as: Niraparib
Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days
Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)
The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.
Time frame: From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days
Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation
The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death
Time frame: From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days
Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA)
Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment
Time frame: From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days
Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation
Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment
Time frame: From date of last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment, up to 7 years, 7 months and 4 days
Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA)
Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.
Time frame: From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days
Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation
Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.
Time frame: From treatment randomization to the earlier of the date of disease progression on the next anti-cancer therapy following study treatment or death due to any cause, up to 7 years, 7 months and 4 days
Overall Survival in Cohort With Germline BRCA Mutation (gBRCA)
Overall survival was defined as the date of randomization to the date of death by any cause.
Time frame: From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days
Overall Survival in Cohort With No Germline BRCA Mutation
Overall survival was defined as the date of randomization to the date of death by any cause.
Time frame: From treatment randomization to date of death by any cause, up to 7 years, 7 months and 4 days
Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)
TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.
Time frame: From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days
Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation
TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.
Time frame: From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Cycle 1 Day 1, Each cycle was of 28 days) and up to 7 years, 7 months and 4 days
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 4 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and at Cycle 6 (Each cycle was of 28 days)
Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose on Day 1) and up to 7 years, 7 months and 4 days
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Baseline
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.
Time frame: At Baseline
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 2
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 2 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 4
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 4 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Cycle 6
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 6 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With Germline BRCA at Post-progression
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: Up to 7 years, 7 months and 4 days
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Baseline
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.
Time frame: At Baseline
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 2
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 2 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 4
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 4 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Cycle 6
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: At Cycle 6 (Each cycle was of 28 days)
Number of Participants With Response to Neuropathy Questionnaire in Cohort With no Germline BRCA at Post-progression
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
Time frame: Up to 7 years, 7 months and 4 days
Number of Participants With Concordance of a Candidate Companion BRAC Analysis Diagnostic Test Compared to the Centralized BRCA Mutation Test Used in This Study
This will never be analyzed since the data for the candidate companion BRAC analysis diagnostic test was not collected which was to be compared with centralized BRCA mutation test used in this study.
Time frame: Up to 7 years, 7 months and 4 days
Number of Participants With Concordance of a Candidate Companion HRD Diagnostic Test Compared to the HRD Test Used in This Study
This will never be analyzed since the data for the candidate companion HRD diagnostic test was not collected which was to be compared with HRD test used in this study.
Time frame: Up to 7 years, 7 months and 4 days
Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. Data presented for this outcome measure is based on the data cut-off date of 31-March-2021, which aligns with the time of the study unblinding.
Time frame: Up to 7 years, 7 months and 6 days
Number of Participants With Non-serious AEs and SAEs (Post-study Unblinding)
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. The data is presented for post-study unblinding duration 01-Apr-2021 to 26-Dec-2021
Time frame: Up to 8 months, 26 days
Number of Participants With Non-serious AEs and SAEs in FE Sub-study
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
Time frame: Up to 2 years, 3 months and 11 days
Number of Participants With Non-serious AEs and SAEs in QTc Sub-study
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
Time frame: Up to 5 years 10 months and 22 days
Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study)
Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib.
Time frame: Pre-dose and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study)
Blood samples were collected at indicated time points to analyze the AUC(0-last) of niraparib.
Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)
Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib.
Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Time to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study)
Blood samples were collected at indicated time points to analyze the tmax of niraparib.
Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study)
Blood samples were collected at indicated time points to analyze the t1/2 of niraparib.
Time frame: Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose
Number of Participants With Maximum Post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) Greater Than Pre-specified Thresholds
12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval \>450 and \<= 480 milliseconds (msec) and \>500 msec.
Time frame: At Baseline (Cycle 1 Day 1, each cycle was of 28 days)
This was a randomized, double-blind study conducted to analyze maintenance with niraparib versus placebo in participants with ovarian cancer.
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 138 | 65 | 234 | 116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 138 | 65 | 234 | 116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing at the time of analysis | 22 | 8 | 31 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 11 | 29 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 2 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject unblinded by sponsor | 12 | 12 | 15 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 72 | 29 | 146 | 68 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 5 | 3 | 8 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 8 | 9 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Transferred to other arm/group | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 7 | 8 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 |
| Milestone | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 8 | 31 | 13 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 8 | 31 | 13 |
| Withdrew: Subject unblinded by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 8 | 18 | 12 |
| Withdrew: Subject moved to rollover study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 9 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
| months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) | 21 (12.9 to NA) | 5.5 (3.8 to 7.2) |
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
| months | Non-gBRCAmut HRD+ Niraparib | Non-gBRCAmut HRD+ Placebo |
|---|---|---|
| Progression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+) | 12.9 (8.1 to 15.9) | 3.8 (3.5 to 5.7) |
PFS was defined as the time between randomization and disease progression or death from any cause. Computed tomography or magnetic resonance imaging to assess disease progression was performed at baseline, every 8 weeks through cycle 14, and then every 12 weeks until treatment discontinuation. The objective assessment of disease progression was determined by means of central radiologic and clinical review, according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, which was performed in a blinded fashion.PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Progression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation | 9.3 (7.2 to 11.2) | 3.9 (3.7 to 5.5) |
The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.
| Months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA) | 19.1 (14.6 to 21.9) | 8.6 (6.9 to 12.2) |
The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Time to First Subsequent Therapy in Cohort With No Germline BRCA Mutation | 12.4 (10.9 to 14.5) | 7.4 (5.9 to 8.7) |
Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment
| Months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Chemotherapy-Free Interval in Cohort With Germline BRCA Mutation (gBRCA) | 20.0 (16.2 to 23.3) | 9.4 (7.9 to 10.4) |
Chemotherapy-Free Interval was defined as the time from the last platinum therapy prior to randomization to the initiation of the next anti-cancer therapy after maintenance treatment
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Chemotherapy-Free Interval in Cohort With No Germline BRCA Mutation | 13.4 (11.3 to 14.8) | 8.7 (6.9 to 10.0) |
Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.
| Months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Progression-Free Survival 2 in Cohort With Germline BRCA Mutation (gBRCA) | 29.9 (24.8 to 33.4) | 22.7 (19.5 to 25.9) |
Progression-Free Survival 2 was defined as the date of randomization in the current study to the earlier date of assessment of progression on the next anti-cancer therapy following study treatment or death due to any cause. Progression was determined by the investigator via clinical and radiographic assessment using the same criteria as used in the current study.
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Progression-Free Survival 2 in Cohort With No Germline BRCA Mutation | 19.5 (17.1 to 22.3) | 16.1 (13.6 to 22.8) |
Overall survival was defined as the date of randomization to the date of death by any cause.
| Months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Overall Survival in Cohort With Germline BRCA Mutation (gBRCA) | 40.9 (34.9 to 52.9) | 38.1 (27.6 to 47.3) |
Overall survival was defined as the date of randomization to the date of death by any cause.
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Overall Survival in Cohort With No Germline BRCA Mutation | 31.0 (27.8 to 35.6) | 34.8 (27.9 to 41.4) |
TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.
| Months | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA) | 29.7 (23.3 to 33.4) | 19.6 (14.4 to 25.5) |
TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.
| Months | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Time to Second Subsequent Therapy in Cohort With No Germline BRCA Mutation | 20.3 (18.0 to 23.4) | 16.7 (14.9 to 21.3) |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 2 | -0.8 ± 4.58 | -0.3 ± 3.19 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 4 | -0.1 ± 4.07 | -0.3 ± 3.88 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Cycle 6 | 0.5 ± 3.77 | -0.5 ± 4.27 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With Germline BRCA at Post-progression | -0.751 ± 4.4342 | -1.324 ± 4.5034 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2 | -1.0 ± 3.79 | -0.3 ± 2.84 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 4 | -0.7 ± 4.16 | -0.9 ± 4.23 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 6 | -0.2 ± 3.76 | -0.9 ± 3.43 |
Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from "not at all" (0) to "very much" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 ("severely symptomatic") to 32 ("asymptomatic"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Post-progression | -2.595 ± 5.5700 | -1.801 ± 4.0290 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in European Quality of Life Scale, 5-Dimensions (EQ-5D-5L) in Cohort With Germline BRCA at Cycle 2 | -0.008 ± 0.1092 | -0.008 ± 0.1354 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 4 | -0.010 ± 0.1225 | -0.035 ± 0.1156 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Cycle 6 | 0.002 ± 0.1116 | -0.004 ± 0.1463 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With Germline BRCA at Post-progression | -0.041 ± 0.1192 | -0.013 ± 0.1580 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 2 | -0.007 ± 0.1013 | -0.011 ± 0.1015 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 4 | -0.004 ± 0.1077 | -0.014 ± 0.0870 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Cycle 6 | 0.005 ± 0.1097 | -0.011 ± 0.0949 |
EQ-5D-5L is a well-validated, general preference-based, health-related Quality of Life (QoL) instrument. The EQ-5D-5L encompasses 5 domains, asking participants to rate their perceived health state today on the following dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 possible levels: "no problems" (Level 1), "slight problems" (Level 2), "moderate problems" (Level 3), "severe problems" (Level 4), and "extreme problems" (Level 5). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Scores on a scale | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Change From Baseline in EQ-5D-5L in Cohort With no Germline BRCA at Post-progression | -0.047 ± 0.1355 | -0.050 ± 0.1351 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.
| Participants | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 47 | 26 |
| Feet, 1-A little bit | 32 | 12 |
| Feet, 2-Somewhat | 24 | 9 |
| Feet, 3-Quite a bit | 21 | 10 |
| Feet, 4-Very much | 9 | 6 |
| Hands, 0-Not at all | 80 | 37 |
| Hands, 1-A little bit | 28 | 13 |
| Hands, 2-Somewhat | 8 | 6 |
| Hands, 3-Quite a bit | 14 | 5 |
| Hands, 4-Very much | 3 | 2 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 48 | 25 |
| Feet, 1-A little bit | 22 | 5 |
| Feet, 2-Somewhat | 17 | 15 |
| Feet, 3-Quite a bit | 20 | 10 |
| Feet, 4-Very much | 8 | 3 |
| Hands, 0-Not at all | 73 | 31 |
| Hands, 1-A little bit | 19 | 16 |
| Hands, 2-Somewhat | 13 | 6 |
| Hands, 3-Quite a bit | 7 | 2 |
| Hands, 4-Very much | 3 | 2 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 47 | 20 |
| Feet, 1-A little bit | 22 | 6 |
| Feet, 2-Somewhat | 20 | 7 |
| Feet, 3-Quite a bit | 15 | 8 |
| Feet, 4-Very much | 6 | 2 |
| Hands, 0-Not at all | 70 | 29 |
| Hands, 1-A little bit | 18 | 6 |
| Hands, 2-Somewhat | 16 | 3 |
| Hands, 3-Quite a bit | 4 | 4 |
| Hands, 4-Very much | 2 | 1 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 44 | 17 |
| Feet, 1-A little bit | 17 | 5 |
| Feet, 2-Somewhat | 13 | 7 |
| Feet, 3-Quite a bit | 15 | 5 |
| Feet, 4-Very much | 9 | 2 |
| Hands, 0-Not at all | 54 | 21 |
| Hands, 1-A little bit | 25 | 8 |
| Hands, 2-Somewhat | 10 | 4 |
| Hands, 3-Quite a bit | 6 | 2 |
| Hands, 4-Very much | 2 | 1 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | gBRCA Niraparib | gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 31 | 15 |
| Feet, 1-A little bit | 20 | 9 |
| Feet, 2-Somewhat | 7 | 3 |
| Feet, 3-Quite a bit | 15 | 7 |
| Feet, 4-Very much | 7 | 3 |
| Hands, 0-Not at all | 44 | 26 |
| Hands, 1-A little bit | 18 | 4 |
| Hands, 2-Somewhat | 8 | 3 |
| Hands, 3-Quite a bit | 7 | 4 |
| Hands, 4-Very much | 3 | 0 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit"). Baseline was latest non-missing pre-dose assessment on or before randomization date.
| Participants | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 71 | 40 |
| Feet, 1-A little bit | 58 | 26 |
| Feet, 2-Somewhat | 37 | 16 |
| Feet, 3-Quite a bit | 43 | 21 |
| Feet, 4-Very much | 18 | 9 |
| Hands, 0-Not at all | 120 | 48 |
| Hands, 1-A little bit | 56 | 37 |
| Hands, 2-Somewhat | 28 | 12 |
| Hands, 3-Quite a bit | 15 | 11 |
| Hands, 4-Very much | 8 | 2 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 69 | 32 |
| Feet, 1-A little bit | 39 | 17 |
| Feet, 2-Somewhat | 30 | 12 |
| Feet, 3-Quite a bit | 34 | 18 |
| Feet, 4-Very much | 9 | 8 |
| Hands, 0-Not at all | 100 | 44 |
| Hands, 1-A little bit | 38 | 24 |
| Hands, 2-Somewhat | 20 | 19 |
| Hands, 3-Quite a bit | 17 | 5 |
| Hands, 4-Very much | 4 | 3 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 54 | 31 |
| Feet, 1-A little bit | 37 | 16 |
| Feet, 2-Somewhat | 34 | 17 |
| Feet, 3-Quite a bit | 20 | 11 |
| Feet, 4-Very much | 9 | 5 |
| Hands, 0-Not at all | 89 | 43 |
| Hands, 1-A little bit | 29 | 21 |
| Hands, 2-Somewhat | 14 | 10 |
| Hands, 3-Quite a bit | 14 | 3 |
| Hands, 4-Very much | 6 | 1 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 43 | 16 |
| Feet, 1-A little bit | 29 | 10 |
| Feet, 2-Somewhat | 30 | 11 |
| Feet, 3-Quite a bit | 18 | 9 |
| Feet, 4-Very much | 5 | 5 |
| Hands, 0-Not at all | 68 | 29 |
| Hands, 1-A little bit | 30 | 10 |
| Hands, 2-Somewhat | 13 | 6 |
| Hands, 3-Quite a bit | 9 | 5 |
| Hands, 4-Very much | 3 | 0 |
A Neuropathy Questionnaire measures the participant's symptom experience over the past 7 days using a 5-point Likert scale of "not at all" (0) to "very much" (4). There are 2 items that ask if the participant's feet (item 1) or hands (item 2) feel numb or have prickling/tingling feelings. The Neuropathy Questionnaire was used to determine the chemotherapy-induced peripheral neuropathy (CIPN) status of each participant as well as provide an anchor for interpreting the impact of CIPN on participant's QoL. Two thresholds were used. For the first, a participant was determined to have CIPN if a score greater than 0 ("not at all") was recorded for either item. For the second, CIPN was assigned if a participant recorded a score greater than 1 ("a little bit").
| Participants | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|
| Feet, 0-Not at all | 57 | 32 |
| Feet, 1-A little bit | 45 | 12 |
| Feet, 2-Somewhat | 23 | 16 |
| Feet, 3-Quite a bit | 19 | 16 |
| Feet, 4-Very much | 5 | 8 |
| Hands, 0-Not at all | 88 | 48 |
| Hands, 1-A little bit | 35 | 15 |
| Hands, 2-Somewhat | 13 | 9 |
| Hands, 3-Quite a bit | 7 | 10 |
| Hands, 4-Very much | 3 | 1 |
This will never be analyzed since the data for the candidate companion BRAC analysis diagnostic test was not collected which was to be compared with centralized BRCA mutation test used in this study.
No measurements were reported for this outcome.
This will never be analyzed since the data for the candidate companion HRD diagnostic test was not collected which was to be compared with HRD test used in this study.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. Data presented for this outcome measure is based on the data cut-off date of 31-March-2021, which aligns with the time of the study unblinding.
| Participants | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo |
|---|---|---|---|---|
| Non-serious AEs | 136 | 62 | 231 | 110 |
| SAEs | 51 | 9 | 76 | 20 |
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events. The data is presented for post-study unblinding duration 01-Apr-2021 to 26-Dec-2021
| Participants | gBRCA Niraparib (PSU) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|
| Non-serious AEs | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
| Participants | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Non-serious AEs | 4 | 6 |
| SAEs | 1 | 0 |
An AE is any untoward medical occurrence that occurs in a participants or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an important medical event(s) as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
| Participants | QTc Sub-study: Niraparib |
|---|---|
| Non-serious AEs | 24 |
| SAEs | 12 |
Blood samples were collected at indicated time points to analyze AUC(0-infinity) of niraparib.
| Nanograms*hour per milliliter | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-infinity]) Following Administration of Niraparib (FE Sub-study) | 29016.1 ± 18405.23 | 31194 ± 16894.88 |
Blood samples were collected at indicated time points to analyze the AUC(0-last) of niraparib.
| Nanograms*hour per milliliter | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC[0-last]) Following Administration of Niraparib (FE Sub-study) | 28638.1 ± 17911.86 | 27186.4 ± 14111.37 |
Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib.
| Nanograms per milliliter | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study) | 803.7 ± 403.35 | 582.1 ± 228.57 |
Blood samples were collected at indicated time points to analyze the tmax of niraparib.
| Hour | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Time to Reach Maximum (Tmax) Following Administration of Niraparib (FE Sub-study) | 3.1 (1.7 to 6.1) | 6.1 (1.2 to 23) |
Blood samples were collected at indicated time points to analyze the t1/2 of niraparib.
| Hour | FE Niraparib Fasted | FE Niraparib Fed |
|---|---|---|
| Terminal Elimination Half-life (t1/2) Following Administration of Niraparib (FE Sub-study) | 50.5 ± 17.87 | 47.9 ± 17.54 |
12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval \>450 and \<= 480 milliseconds (msec) and \>500 msec.
| Participants | QTc Sub-study: Niraparib |
|---|---|
| >450 msec | 2 |
| >480 msec | 0 |
| >500 msec | 0 |
Collected over All-cause mortality, non-serious AEs (non-SAEs) and SAEs were collected up to 8 years, 6 months and 6 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| gBRCA Niraparib | 72/136 (52.9%) | 51/136 (37.5%) | 136/136 (100%) |
| gBRCA Placebo | 29/65 (44.6%) | 9/65 (13.8%) | 62/65 (95.4%) |
| Non-gBRCA Niraparib | 146/231 (63.2%) | 76/231 (32.9%) | 231/231 (100%) |
| Non-gBRCA Placebo | 68/114 (59.6%) | 20/114 (17.5%) | 110/114 (96.5%) |
| FE Niraparib Fasted | 0/16 (0%) | 1/16 (6.3%) | 4/16 (25%) |
| FE Niraparib Fed | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| QTc Sub-study: Niraparib | 5/26 (19.2%) | 12/26 (46.2%) | 24/26 (92.3%) |
| gBRCA Niraparib (Post-study Unblinding [PSU]) | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| gBRCA Placebo (PSU) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Non-gBRCA Niraparib (PSU) | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Non-gBRCA Placebo (PSU) | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Niraparib Fasted | FE Niraparib Fed | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 18/136 | 0/65 | 23/231 | 0/114 | 0/16 | 0/16 | 3/26 | 0/22 | 0/8 | 0/31 | 0/12 |
| AnaemiaBlood and lymphatic system disorders | 4/136 | 0/65 | 13/231 | 0/114 | 0/16 | 0/16 | 2/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Urinary tract infectionInfections and infestations | 1/136 | 1/65 | 2/231 | 1/114 | 1/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/136 | 1/65 | 0/231 | 0/114 | 0/16 | 0/16 | 0/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Small intestinal obstructionGastrointestinal disorders | 3/136 | 0/65 | 6/231 | 4/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| AscitesGastrointestinal disorders | 2/136 | 0/65 | 0/231 | 2/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Abdominal painGastrointestinal disorders | 1/136 | 0/65 | 1/231 | 1/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Hip fractureInjury, poisoning and procedural complications | 1/136 | 0/65 | 0/231 | 0/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| OesophagitisGastrointestinal disorders | 0/136 | 0/65 | 0/231 | 0/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Procedural complicationInjury, poisoning and procedural complications | 0/136 | 0/65 | 0/231 | 0/114 | 0/16 | 0/16 | 1/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Event | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Niraparib Fasted | FE Niraparib Fed | QTc Sub-study: Niraparib | gBRCA Niraparib (Post-study Unblinding [PSU]) | gBRCA Placebo (PSU) | Non-gBRCA Niraparib (PSU) | Non-gBRCA Placebo (PSU) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 106/136 | 23/65 | 168/231 | 41/114 | 0/16 | 0/16 | 13/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 74/136 | 5/65 | 111/231 | 7/114 | 1/16 | 0/16 | 12/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 13/136 | 2/65 | 93/231 | 4/114 | — | — | 13/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| FatigueGeneral disorders | 66/136 | 19/65 | 110/231 | 38/114 | 0/16 | 1/16 | 13/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| VomitingGastrointestinal disorders | 57/136 | 10/65 | 74/231 | 21/114 | 0/16 | 1/16 | 10/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| ConstipationGastrointestinal disorders | 56/136 | 12/65 | 96/231 | 23/114 | 0/16 | 1/16 | 9/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| NeutropeniaBlood and lymphatic system disorders | 24/136 | 3/65 | 42/231 | 3/114 | 0/16 | 0/16 | 10/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| HeadacheNervous system disorders | 52/136 | 7/65 | 52/231 | 14/114 | 0/16 | 0/16 | 5/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Abdominal painGastrointestinal disorders | 34/136 | 17/65 | 63/231 | 39/114 | 0/16 | 0/16 | 7/26 | 0/22 | 0/8 | 0/31 | 0/13 |
| Dry mouthGastrointestinal disorders | 19/136 | 2/6 | 19/231 | 5/114 | 0/16 | 0/16 | 0/26 | 0/22 | — | 0/31 | 0/13 |
The baseline analysis population was the intent-to-treat population, defined as all randomized participants with participants analyzed according to the study drug assigned via randomization
| Age, Customized(Participants) | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 64 years | 110 | 49 | 130 | 69 | 5 | 5 | 16 | 384 |
| >=65 years | 28 | 16 | 104 | 47 | 3 | 4 | 10 | 212 |
| Sex: Female, Male(Participants) | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 138 | 65 | 234 | 116 | 8 | 9 | 26 | 596 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | gBRCA Niraparib | gBRCA Placebo | Non-gBRCA Niraparib | Non-gBRCA Placebo | FE Sub-study: Fasted/Fed | FE Sub-study: Fed/Fasted | QTc Sub-study: Niraparib | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Asian | 2 | 3 | 10 | 4 | 0 | 0 | 1 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 1 | 1 | 4 | 1 | 1 | 0 | 3 | 11 |
| White | 123 | 55 | 201 | 101 | 6 | 9 | 21 | 516 |
| Unknown or Not Reported | 11 | 6 | 19 | 10 | 0 | 0 | 0 | 46 |
Showing the first 100 of 112 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2013 to primary completion in Apr 2016, 34 months.
Results were first posted in May 2019, 3 years after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 34 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib